NCT02392611: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer |
|
|
| Completed | 1 | 33 | US | Alobresib, GS-5829, Exemestane, Aromasin®, Fulvestrant, Faslodex® | Gilead Sciences | Solid Tumors and Lymphomas | 10/17 | 10/17 | | |
